|
Main Category: Anxiety / Stress Also Included In: Regulatory Affairs / Drug Approvals ; Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry Article Date: 23 Aug 2008 - 1:00 PDT printer friendly ...
|
|
Eli Lilly and Co and Boehringer Ingelheim have announced that the European Commission has approved the use of Cymbalta for the treatment of Generalised Anxiety Disorder .
|
|
... making this the longest data analysis of duloxetine for the treatment of DPNP." During the course of the eight-week acute therapy and 26-week maintenance therapy periods, the most common treatment-emergent adverse events (those occurring in more ...
|
|
... the medical conditions seen shortly after the attacks and those being treated now has been the transformation from acute illnesses to chronic ones. Respiratory problems, gastrointestinal conditions and post-traumatic stress disorder are common and ...
|
|
... also explains the tests and treatments for IC/PBS, including bladder retraining, physical therapy, physical activity, stress reduction, medication, bladder stretching, nerve stimulation, and surgery. For an online version of this booklet, go to: ...
|
|
... received as out-of-hospital benefits - Not covered All pre-existing and/or chronic medical conditions - Not covered (Acute exacerbation of pre-existing and chronic medical conditions will be covered in Emergency Room only) Healthcare Services ...
|
|
Whether it's because of stress, kids or other reasons, all of us have struggled to fall asleep at some point.
|